Literature DB >> 16624631

Systematic identification and classification of adverse events in human research.

David I Silverman1, Lisanne Cirullo, Nicholas A DeMartinis, Kathryn Damato, Margaret DeMeo, Gustavo A Fernandez, Laura Glynn, Upendra Hegde, Elizabeth Laskay, Robin Leger, Khamis Abu-Hasaballah, Joan M Caron.   

Abstract

Widely accepted standards and safeguards for research participants now include systematic surveillance and recording of adverse events. In the absence of a uniform regulation or structure for such reporting, each institution must now establish suitable yet efficient procedures to accomplish this task. We report herein our single center experience with a customized data collection, storage and review system specifically designed to identify and react appropriately to adverse events. Adverse events are classified by each investigator using three criteria in specific order: seriousness, expectedness and relatedness to the investigational intervention. Once classified, events are entered into an online database that includes collation, retrieval and search capabilities. Events meeting specified criteria are reviewed and adjudicated on a weekly basis by The University of Connecticut Research Adverse Events Committee, which makes advisory recommendations to the hospital's two Institutional Research Boards ranging from modification of informed consent to study suspension. Three hundred and seventy-one serious adverse events from > 900 studies were reviewed in the previous academic year. Our system, which combines timely on-line reporting with regular surveillance, provides a potential model that meets the need for comprehensive yet practical adverse events assessment and reporting.

Entities:  

Mesh:

Year:  2006        PMID: 16624631     DOI: 10.1016/j.cct.2006.02.005

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  2 in total

Review 1.  An automated standardized system for managing adverse events in clinical research networks.

Authors:  Rachel L Richesson; Jamie F Malloy; Kathleen Paulus; David Cuthbertson; Jeffrey P Krischer
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  Margaret C Bell; Patricia R Robuck; Elizabeth C Wright; Marina S Mihova; Charlotte Hofmann; Jennifer L De Santo; Susan L Milstein; Pamela A Richtmyer; Janel L Shelton; Maureen Cormier; Debra L King; Choon J Park; Wallis A Molchen; Yoon Park; Michelle Kelley
Journal:  Clin Trials       Date:  2009-11-04       Impact factor: 2.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.